This inventor holds 1 USPTO granted patent. Top assignees: Arizona State University, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2022.
Company Filing History:
1 out of 2,159 
1 out of 3,693 
Years Active: 2022
Title: Ji Qui: Innovator in Cancer Biomarkers
Introduction
Ji Qui is an accomplished inventor based in Chandler, AZ (US). He has made significant contributions to the field of cancer research, particularly in the early detection of basal-like breast cancer. His innovative work has the potential to improve patient outcomes through the identification of specific biomarkers.
Latest Patents
Ji Qui holds a patent titled "Plasma autoantibody biomarkers for basal-like breast cancer." This patent addresses the development of antibodies that cancer patients produce in response to tumor-derived proteins. These antibodies serve as potential biomarkers for the early detection of basal-like breast cancer. His research has identified twenty-eight antigens that could be crucial for this purpose. Additionally, a 13-AAb classifier has been developed, which differentiates patients with basal-like breast cancer from healthy controls, achieving 33% sensitivity at 98% specificity.
Career Highlights
Throughout his career, Ji Qui has worked with notable institutions, including Arizona State University and the United States Department of Health and Human Services. His work has been instrumental in advancing the understanding of cancer biomarkers and their applications in clinical settings.
Collaborations
Ji Qui has collaborated with esteemed colleagues such as Joshua LaBaer and Jie Wang. These partnerships have further enriched his research and contributed to the development of innovative solutions in cancer detection.
Conclusion
Ji Qui's contributions to cancer research, particularly in the identification of biomarkers for basal-like breast cancer, highlight his role as a leading inventor in the field. His work not only advances scientific knowledge but also holds promise for improving early detection and treatment options for patients.